Mylan Pharmaceuticals Inc, Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Mylan Pharmaceuticals Inc, Pharmaceutical Import Records from India — 26 Products, $94.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan Pharmaceuticals Inc, — Pharmaceutical Importer Profile (2026) | 26 Products, $94.4M Trade | TransData Nexus

Mylan Pharmaceuticals Inc,

Pharmaceutical Importer · United States · Cardiovascular Focus · $94.4M Total Trade · DGFT Verified

Mylan Pharmaceuticals Inc, is a pharmaceutical importer based in United States with a total trade value of $94.4M across 26 products in 12 therapeutic categories. Based on 1,919 verified import shipments from Indian Customs (DGFT) records, Mylan Pharmaceuticals Inc, is the #1 buyer in 5 products including Pantoprazole, Valsartan, Acyclovir. Mylan Pharmaceuticals Inc, sources from 5 verified Indian suppliers, with Mylan Laboratories Limited accounting for 98.0% of imports.

Mylan Pharmaceuticals Inc, — Import Portfolio & Supplier Network

Mylan Pharmaceuticals Inc, import network — 26 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan Pharmaceuticals Inc,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$52.7M	1,549	98.0%
Unichem Laboratories Limited	$491.9K	26	0.9%
Usv Private Limited

What Formulations Does Mylan Pharmaceuticals Inc, Import?

Formulation	Value	Ships
Pantoprazole sodium delayed-release	$2.9M	65
Pantoprazole sodium delayed release	$2.2M	47
Metformin hydrochloride tablets USP	$1.5M	32
Valsartan and hydrochlorothiazide	$1.2M	24
Metoprolol succinate extended release	$868.0K	24
Potassium chloride extended-release	$784.8K	20
Metformin hydrochloride tablets USP	$750.0K	15
Lithium carbonate extended release	$620.7K	15
Atorvastatin calcium tablets USP 80 MG	$600.0K	12
Atorvastatin calcium tablets USP 40 MG	$600.0K	12
Amlodipine and valsartan tablets USP	$565.6K	13
Amlodipine and valsartan tablets USP	$533.8K	11
Lansoprazole delayed release capsules	$480.5K	14
Potassium chloride extended release	$461.7K	12
Atorvastatin calcium tablets USP 40 MG	$450.0K	9

Mylan Pharmaceuticals Inc, imports 699 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 26 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atorvastatin	Cardiovascular	$11.4M	228	0.5%	3
2	Pantoprazole	Gastrointestinal	$11.2M	223	0.4%	1
3	Metoprolol	Cardiovascular	$10.1M	202	0.5%	5
4	Valsartan	Cardiovascular	$8.1M	162	2.4%	1
5	Citalopram	CNS & Psychiatric	$6.2M	129	1.1%	3
6	Calcium	Vitamins & Supplements	$6.0M	120	0.3%	3
7	Metformin	Diabetes & Endocrine	$4.8M	95	1.0%	9
8	Amlodipine	Cardiovascular	$4.5M	89	0.0%	10
9	Telmisartan	Cardiovascular	$3.9M	77	0.0%	3
10	Hydrochlorothiazide	Diuretics	$3.3M	65	0.5%	10
11	Fenofibrate	Lipid & Metabolism	$3.0M	75	2.4%	9
12	Lansoprazole	Gastrointestinal	$2.8M	56	0.6%	3
13	Sodium	Nutritional Supplements	$2.5M	50	0.7%	12
14	Acyclovir	Antivirals	$2.2M	44	0.9%	1
15	Valacyclovir	Antivirals	$2.2M	44	1.2%	1
16	Potassium	Nutritional Supplements	$1.9M	39	0.3%	2
17	Saxagliptin	Advanced Diabetes Medications	$1.7M	37	21.4%	1
18	Atovaquone	Antimalarial & Antiparasitic	$1.6M	32	0.1%	7
19	Esomeprazole	Gastrointestinal	$1.3M	26	0.3%	16
20	Proguanil	Antimalarial & Antiparasitic	$1.3M	26	0.1%	3
21	Magnesium	Vitamins & Supplements	$1.1M	21	0.3%	14
22	Iron	Vitamins & Supplements	$900.0K	18	0.2%	6
23	Diltiazem	Cardiovascular	$886.9K	22	3.8%	7
24	Verapamil	Cardiovascular	$750.0K	15	0.5%	9
25	Diazepam	CNS & Psychiatric	$697.1K	18	8.0%	2
26	Ras	Ayurvedic & Herbal Products	$300.0K	6	0.1%	10

Mylan Pharmaceuticals Inc, imports 26 pharmaceutical products across 12 categories into United States totaling $94.4M. The company is the #1 buyer for 5 products: Pantoprazole, Valsartan, Acyclovir, Valacyclovir, Saxagliptin.

Mylan Pharmaceuticals Inc, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan Pharmaceuticals Inc., established in 1961, is a prominent pharmaceutical company headquartered in Canonsburg, Pennsylvania. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris Inc. This strategic merger expanded Viatris's global footprint, combining Mylan's extensive portfolio of generic and specialty pharmaceuticals with Upjohn's established presence in the market.

As a leading player in the pharmaceutical industry, Viatris operates across various segments, including generics, specialty medicines, and active pharmaceutical ingredients (APIs). The company's diverse product range spans multiple therapeutic areas, such as oncology, cardiovascular, respiratory, and dermatology. Viatris's mission focuses on providing access to medicines, sustainable operations, and advancing patient care worldwide.

2Distribution Network

Viatris's distribution network is extensive, encompassing a global reach that ensures the availability of its products in numerous countries. In the United States, the company maintains a robust logistics infrastructure, including multiple warehouse locations strategically positioned to facilitate efficient distribution. This network enables Viatris to serve a wide array of customers, from retail pharmacies to healthcare institutions, ensuring timely delivery of pharmaceutical products across the nation.

3Industry Role

Within the United States pharmaceutical supply chain, Viatris functions as a primary wholesaler and distributor. The company sources a significant portion of its pharmaceutical products from international markets, including India, to meet the diverse needs of the U.S. healthcare system. By importing a wide range of finished pharmaceutical formulations, Viatris plays a crucial role in ensuring the availability of essential medications to patients and healthcare providers across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan Pharmaceuticals Inc,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Viatris's sourcing strategy exhibits a high degree of concentration, with a substantial majority of its pharmaceutical imports originating from a single supplier, Mylan Laboratories Limited. This supplier accounted for approximately 98% of the total import value from India, highlighting a significant dependency on this source. While such concentration can lead to cost efficiencies and streamlined supply chain management, it also introduces potential risks. Any disruptions affecting Mylan Laboratories Limited could have a considerable impact on Viatris's ability to meet market demand. The stability of this relationship is critical, and Viatris must implement strategies to mitigate risks associated with supplier dependency.

2Supply Chain Resilience

Viatris's supply chain resilience is closely tied to the stability and reliability of its primary supplier, Mylan Laboratories Limited. The company's sourcing profile indicates a heavy reliance on this single supplier for a vast majority of its imports. This concentration suggests that while Viatris benefits from streamlined operations and potential cost advantages, it also faces challenges in terms of supply chain diversification. To enhance resilience, Viatris may consider diversifying its supplier base and establishing contingency plans to address potential disruptions.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for drug imports, ensuring that all imported drugs meet the same standards of quality, safety, and efficacy as domestically produced drugs.

For Indian pharmaceutical exporters, obtaining FDA approval is essential for entering the U.S. market. This process involves registering manufacturing facilities, listing drug products, and ensuring compliance with FDA regulations. The FDA's Regulatory Procedures Manual provides detailed guidance on the importation process, including requirements for drug labeling, facility registration, and compliance with good manufacturing practices (GMP).

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All foreign drug establishments whose products are imported must register with the FDA and list all their drug products intended for U.S. distribution. This registration ensures that the FDA is notified of all regulated products imported into the United States.

Compliance with Good Manufacturing Practices (GMP) is mandatory for all pharmaceutical products imported into the U.S. The FDA recognizes various GMP certifications, including those from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications demonstrate that manufacturing facilities adhere to internationally recognized standards for quality and safety.

Mylan Pharmaceuticals Inc, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Viatris's product strategy focuses on therapeutic areas with high demand and significant market potential. The company's imports from India predominantly include cardiovascular medications, gastrointestinal drugs, and vitamins and supplements. This focus aligns with the growing prevalence of chronic diseases and the increasing need for preventive healthcare solutions in the United States. By sourcing these products from India, Viatris can offer cost-effective alternatives to branded medications, thereby enhancing patient access to essential treatments.

2Sourcing Profile

Viatris's sourcing strategy emphasizes the procurement of generic drugs, particularly finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. India's well-established pharmaceutical manufacturing sector, characterized by its adherence to international quality standards and cost competitiveness, makes it a preferred sourcing destination for Viatris. This approach enables Viatris to maintain a diverse and reliable product portfolio while meeting the demands of the U.S. market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Mylan Pharmaceuticals Inc,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Viatris's supply chain, particularly if they can offer high-quality products that meet FDA standards and competitive pricing. Gaps in Viatris's current sourcing include a limited number of suppliers, which presents an opportunity for diversification. Indian exporters can capitalize on this by ensuring compliance with regulatory requirements and demonstrating the ability to meet Viatris's quality and supply expectations.

2Requirements & Qualifications

Indian exporters seeking to supply Viatris and enter the U.S. market must obtain FDA approval, which involves registering manufacturing facilities, listing drug products, and ensuring compliance with GMP standards. Additionally, products must meet FDA labeling requirements, including providing accurate and truthful information in English. Compliance with these standards is essential for successful market entry.

3How to Approach

Frequently Asked Questions — Mylan Pharmaceuticals Inc,

What products does Mylan Pharmaceuticals Inc, import from India?

Mylan Pharmaceuticals Inc, imports 26 pharmaceutical products across 12 categories. Top imports: Atorvastatin ($11.4M), Pantoprazole ($11.2M), Metoprolol ($10.1M), Valsartan ($8.1M), Citalopram ($6.2M).

Who supplies pharmaceuticals to Mylan Pharmaceuticals Inc, from India?

Mylan Pharmaceuticals Inc, sources from 5 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (98.0% of imports, $52.7M).

What is Mylan Pharmaceuticals Inc,'s total pharmaceutical import value?

Mylan Pharmaceuticals Inc,'s total pharmaceutical import value from India is $94.4M, based on 1,919 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan Pharmaceuticals Inc, focus on?

Mylan Pharmaceuticals Inc, imports across 12 categories. The largest: Cardiovascular (41.9%), Gastrointestinal (16.2%), Vitamins & Supplements (8.4%).

Get Full Mylan Pharmaceuticals Inc, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.